Novo Nordisk Advances Novel Obesity Drug LX9851 into Phase 1 Trials
Event summary
- Novo Nordisk initiated a Phase 1 clinical trial for LX9851, an oral, non-incretin obesity drug candidate, on March 23, 2026.
- Lexicon Pharmaceuticals has received $20 million in milestone payments from Novo Nordisk, with potential for up to $1.1 billion more plus royalties.
- The Phase 1 trial will assess safety, tolerability, and pharmacokinetics in 96 overweight or obese individuals and is expected to conclude in Q1 2027.
- LX9851 targets ACSL5, a metabolic pathway involved in fat accumulation, and may activate the ileal brake mechanism to increase satiety.
The big picture
Novo Nordisk's investment in LX9851 signals a continued expansion of its obesity treatment portfolio beyond GLP-1 receptor agonists. The drug’s novel mechanism of action, targeting ACSL5, represents a strategic diversification effort to address unmet needs in a rapidly growing market estimated to reach hundreds of billions of dollars. Lexicon’s deal structure provides significant financial upside, but its success is contingent on Novo Nordisk’s ability to successfully develop and commercialize the drug.
What we're watching
- Clinical Efficacy
- The Phase 1 trial's results will be critical in determining whether LX9851 demonstrates the preclinical efficacy observed with semaglutide and its ability to mitigate weight regain.
- Regulatory Pathway
- Novo Nordisk’s decision to pursue a non-incretin approach could influence the regulatory pathway and potentially expedite approval if it avoids existing incretin-related safety concerns.
- Commercial Landscape
- The success of LX9851 will depend on its ability to differentiate from existing obesity treatments, particularly given the market dominance of Novo Nordisk’s own GLP-1 therapies.
Related topics